Vivos TherapeuticsInc Company Insiders
| VVOS Stock | USD 2.64 0.08 2.94% |
Vivos TherapeuticsInc's insiders are aggressively buying. The analysis of insiders' sentiment of trading Vivos TherapeuticsInc stock suggests that vertually all insiders are extremely bullish at this time. Vivos TherapeuticsInc employs about 114 people. The company is managed by 10 executives with a total tenure of roughly 266 years, averaging almost 26.0 years of service per executive, having 11.4 employees per reported executive.
Vivos TherapeuticsInc's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2023-06-20 | Ronald Kirk Huntsman | Acquired 560 @ 13.25 | View | ||
| 2023-06-16 | Ronald Kirk Huntsman | Acquired 600 @ 13.5 | View | ||
| 2023-06-14 | Ronald Kirk Huntsman | Acquired 400 @ 12.25 | View |
Monitoring Vivos TherapeuticsInc's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Vivos |
Vivos TherapeuticsInc Management Team Effectiveness
The company has return on total asset (ROA) of (0.8843) % which means that it has lost $0.8843 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.2122) %, meaning that it created substantial loss on money invested by shareholders. Vivos TherapeuticsInc's management efficiency ratios could be used to measure how well Vivos TherapeuticsInc manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.91 in 2024. Return On Capital Employed is likely to gain to -4.78 in 2024. At this time, Vivos TherapeuticsInc's Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 27 M in 2024, whereas Total Current Assets are likely to drop slightly above 2.3 M in 2024.Common Stock Shares Outstanding is likely to drop to about 899.6 K in 2024. Net Loss is likely to drop to about (19.2 M) in 2024
Vivos TherapeuticsInc Workforce Comparison
Vivos TherapeuticsInc is rated below average in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 7,004. Vivos TherapeuticsInc claims roughly 114 in number of employees contributing just under 2% to equities under Health Care industry.
Vivos TherapeuticsInc Profit Margins
The company has Profit Margin (PM) of (0.98) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.27) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.27.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.77 | 0.5543 |
|
|
Vivos TherapeuticsInc Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vivos TherapeuticsInc insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vivos TherapeuticsInc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Vivos TherapeuticsInc insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2020-12-01 | 0.375 | 3 | 8 | 2,500 | 433,336 |
Vivos TherapeuticsInc Notable Stakeholders
A Vivos TherapeuticsInc stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Vivos TherapeuticsInc often face trade-offs trying to please all of them. Vivos TherapeuticsInc's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Vivos TherapeuticsInc's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Susan McCullough | CoFounder Operations | Profile | |
| RaeAnn Byrnes | CoFounder Services | Profile | |
| Kirk Huntsman | Chairman CoFounder | Profile | |
| Julie Gannon | Chief Relations | Profile | |
| Nicholas DeGennaro | Senior Division | Profile | |
| John Ballard | Senior Technology | Profile | |
| Ruth Hembree | Senior Services | Profile | |
| Todd Huntsman | CoFounder Technology | Profile | |
| Stephanie Huebner | Senior Integration | Profile | |
| Bradford Amman | Treasurer CFO | Profile |
About Vivos TherapeuticsInc Management Performance
The success or failure of an entity such as Vivos TherapeuticsInc often depends on how effective the management is. Vivos TherapeuticsInc management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Vivos management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Vivos management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.82) | (1.91) | |
| Return On Capital Employed | (5.03) | (4.78) | |
| Return On Assets | (1.27) | (1.33) | |
| Return On Equity | (33.05) | (31.40) |
The data published in Vivos TherapeuticsInc's official financial statements usually reflect Vivos TherapeuticsInc's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Vivos TherapeuticsInc. For example, before you start analyzing numbers published by Vivos accountants, it's critical to develop an understanding of what Vivos TherapeuticsInc's liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of Vivos TherapeuticsInc's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vivos TherapeuticsInc's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Vivos TherapeuticsInc's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vivos TherapeuticsInc. Please utilize our Beneish M Score to check the likelihood of Vivos TherapeuticsInc's management manipulating its earnings.
Vivos TherapeuticsInc Workforce Analysis
Traditionally, organizations such as Vivos TherapeuticsInc use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Vivos TherapeuticsInc within its industry.Vivos TherapeuticsInc Manpower Efficiency
Return on Vivos TherapeuticsInc Manpower
| Revenue Per Employee | 121.1K | |
| Revenue Per Executive | 1.4M | |
| Net Loss Per Employee | 119.1K | |
| Net Loss Per Executive | 1.4M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vivos TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Vivos Stock please use our How to Invest in Vivos TherapeuticsInc guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Vivos Stock analysis
When running Vivos TherapeuticsInc's price analysis, check to measure Vivos TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos TherapeuticsInc is operating at the current time. Most of Vivos TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Vivos TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos TherapeuticsInc's price. Additionally, you may evaluate how the addition of Vivos TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is Vivos TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vivos TherapeuticsInc. If investors know Vivos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vivos TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.14) | Revenue Per Share 11.318 | Quarterly Revenue Growth (0.18) | Return On Assets (0.88) | Return On Equity (5.21) |
The market value of Vivos TherapeuticsInc is measured differently than its book value, which is the value of Vivos that is recorded on the company's balance sheet. Investors also form their own opinion of Vivos TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Vivos TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vivos TherapeuticsInc's market value can be influenced by many factors that don't directly affect Vivos TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vivos TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vivos TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vivos TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.